Patent search ipc:A61K31/4164 Page 1

1.

发明申请
Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors 有权

公开(公告)号：US20250064787A1

公开(公告)日：2025-02-27

申请号：US18933481

申请日：2024-10-31

Applicant: Lilac Therapeutics, Inc.

Inventor： Hongyan Guo , Amy S. Lee , Hyung-Jung Pyun , Devleena M. Shivakumar , Manoj C. Desai , Lianhong Xu , John E. Knox , Zachary ER Newby

IPC: A61K31/4192 , A61K31/19 , A61K31/194 , A61K31/351 , A61K31/381 , A61K31/382 , A61K31/415 , A61K31/4164 , A61K31/422 , A61K31/427 , A61K31/428 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/675 , A61K31/7048 , A61K38/51 , A61K45/06 , C07D231/14 , C07D233/90 , C07D249/06 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/14 , C07D405/04 , C07D405/10 , C07D405/14 , C07D413/10 , C07D417/04 , C07D417/10 , C07F9/6558 , C12N15/113

Abstract: The present disclosure relates to compounds, compositions, and methods for the treatment of primary hyperoxaluria type 1 and recurrent kidney stone formers. The present disclosure is directed to novel substituted heterocyclic carboxylate compounds and methods for their preparation and use as therapeutic or prophylactic agents. In particular, the present disclosure provides novel inhibitors of human glycolate oxidase enzyme, pharmaceutical compositions containing such compounds, and methods for using these compounds to treat primary hyperoxaluria type 1 and recurrent kidney stone formers.

2.

发明申请
SYSTEMS AND DEVICES FOR DELIVERING FLUIDS TO THE EYE AND METHODS OF USE 有权

公开(公告)号：US20250057692A1

公开(公告)日：2025-02-20

申请号：US18933968

申请日：2024-10-31

Applicant: Eyenovia, Inc.

Inventor： Luke W. Clauson , Rex Dwyer , Matthew Newell , Michael Owens

IPC: A61F9/00 , A61K31/135 , A61K31/222 , A61K31/4164 , A61K31/4409 , A61K31/46 , A61K47/02 , A61K47/18

Abstract: A device for delivering a volume of fluid to an eye including a base having a drive mechanism and a disposable fluid cartridge configured to releasably couple to the base to form the device. Related systems, devices, compositions, and methods of use are provided.

3.

发明申请
COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA, MILD HYPEROPIA, AND IRREGULAR ASTIGMATISM 有权

公开(公告)号：US20250049761A1

公开(公告)日：2025-02-13

申请号：US18665291

申请日：2024-05-15

Applicant: Allergan, Inc.

Inventor： Juan Carlos Abad

IPC: A61K31/4178 , A61K9/00 , A61K31/16 , A61K31/27 , A61K31/325 , A61K31/4164 , A61K31/4174 , A61K31/5415 , A61K45/06

Abstract: The present invention is directed to compositions and methods for treating ocular conditions, including presbyopia, mild hyperopia, irregular astigmatism, hyperopic accommodative esotropia, and glaucoma. The compositions can also be used to potentiate or enhance interventions that retard, reverse, or modify the aging process of the crystalline lens and its surrounding tissues. The compositions include a cholinergic agent, such as a muscarinic acetylcholine receptor M3 agonist, and an alpha agonist having an imidazoline group or a non-steroidal anti-inflammatory agent (NSAID) having COX-2 selectivity. It has been found that an alpha agonist having an imidazoline group or non-steroidal anti-inflammatory agent (NSAID) having COX-2 selectivity in combination with a cholinergic agent, such as pilocarpine, act synergistically to improve the accommodative and focusing ability of the eye while minimizing the side effects from each compound.

4.

发明申请
Formulations of Enzalutamide 有权

公开(公告)号：US20250049721A1

公开(公告)日：2025-02-13

申请号：US18931464

申请日：2024-10-30

Applicant: Astellas Pharma Inc. , Medivation Prostate Therapeutics LLC

Inventor： Douglas Alan Lorenz , Sanjay Konagurthu , Randy J. Wald , Jason A. Everett , Sheila Matz , Yuuki Takaishi , Toshiro Sakai , Ryousuke Irie , Shinsuke Oba , Hiroyasu Toyota , Koji Nishimura , Atsushi Kanbayashi

IPC: A61K9/20 , A61K9/10 , A61K9/16 , A61K31/4164 , A61K31/4166 , A61K47/32 , A61K47/38 , C07D233/86

Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

5.

发明申请
COMPOSITIONS AND METHODS OF CLOSTRIDIODIDES DIFFICILE TREATMENT, DECOLONIZATION, AND PREVENTION 有权

公开(公告)号：US20250032515A1

公开(公告)日：2025-01-30

申请号：US18888405

申请日：2024-09-18

Applicant: Wisconsin Alumni Research Foundation

Inventor： Noah Daniel Budi

IPC: A61K31/575 , A61K31/185 , A61K31/198 , A61K31/225 , A61K31/4164 , A61K31/444 , A61K31/65 , A61K31/7048 , A61K38/14 , A61K47/02 , A61P31/04

Abstract: A germinant mixture includes a) a bile acid main germinant, b) an amino acid co-germinant, c) an edible spore solubilizing agent, and d) a divalent metal salt co-germinant. Also described is an oral pharmaceutical composition including the germinant mixture and a pharmaceutically acceptable excipient. A method of treating, decolonizing, and/or preventing C. difficile infection in the gastrointestinal tract of a patient in need thereof includes orally administering the germinant mixture or the oral pharmaceutical composition and an antibiotic that is active against C. difficile to the patient in need thereof.

6.

发明申请
REVITALIZING EYE DROPS 有权

公开(公告)号：US20250032500A1

公开(公告)日：2025-01-30

申请号：US18782664

申请日：2024-07-24

Applicant: Revitalize Energy, Inc.

Inventor： Kyle Guinness

IPC: A61K31/522 , A61K9/00 , A61K31/4164 , A61K33/30 , A61K47/10 , A61K47/18 , A61K47/20 , A61K47/38

Abstract: An ophthalmic composition for tired eye therapy comprising effective amounts of at least one or more stimulants, one or more non-essential amino acids, or one or more cooling agents. Additional compounds for the ophthalmic composition as well as methods of making and using the ophthalmic compositions are further disclosed.

7.

发明申请
METHODS OF TREATING ANDROGENIC ALOPECIA AND/OR SKIN CONDITIONS 有权

公开(公告)号：US20250032457A1

公开(公告)日：2025-01-30

申请号：US18838889

申请日：2021-09-14

Applicant: Eric Rauch

Inventor： Eric Rauch

IPC: A61K31/4174 , A61K8/49 , A61K31/4164 , A61K31/506 , A61K31/56 , A61P17/14 , A61Q7/00 , A61Q19/08

Abstract: Described herein are methods of using one or more azole compounds in treating androgenic alopecia, reducing or stopping hair thinning, reversing hair thinning, promoting hair growth, reversing hairline recession, and/or treating a skin condition.

8.

发明授权
Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereof 有权

公开(公告)号：US12172969B2

公开(公告)日：2024-12-24

申请号：US17681634

申请日：2022-02-25

Applicant: EVOFEM BIOSCIENCES, INC.

Inventor： Richard John Holl , Kurt Nielsen , James Garegnani

IPC: C07D233/94 , A61K31/4164 , A61K31/565 , A61K31/57

Abstract: The present invention is related to deuterated secnidazole, a prodrug thereof, a hydrate thereof, a solvate thereof, a polymorph thereof, or a pharmaceutically acceptable salt thereof and its use for the treatment of bacterial vaginosis or trichomoniasis in a subject in need thereof. The present invention is also related to pharmaceutical compositions and methods and uses of treating bacterial vaginosis, trichomoniasis, amoebiasis, giardiasis, or a combination thereof.